(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 12.63% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.5%.
Repligen's revenue in 2025 is $650,429,000.On average, 7 Wall Street analysts forecast RGEN's revenue for 2025 to be $39,439,187,806, with the lowest RGEN revenue forecast at $39,103,999,431, and the highest RGEN revenue forecast at $39,833,817,900. On average, 6 Wall Street analysts forecast RGEN's revenue for 2026 to be $45,868,781,770, with the lowest RGEN revenue forecast at $44,850,968,730, and the highest RGEN revenue forecast at $46,676,919,480.
In 2027, RGEN is forecast to generate $54,949,319,124 in revenue, with the lowest revenue forecast at $54,949,319,124 and the highest revenue forecast at $54,949,319,124.